Sugi Predict

Sugi Predict / Compounds / SCHEMBL1068166

SCHEMBL1068166

SCHEMBL1068166

CC(=O)SC1CCCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ MAPT P10636 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ HPGD P15428 1/20 0.49
▸ EPHX1 P07099 1/20 0.43
▸ PREP P48147 2/20 0.42
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ USP30 Q70CQ3 1/20 0.41
▸ RECQL P46063 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ NR1H2 P55055 1/20 0.40
▸ GLS O94925 2/20 0.40
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ EPHX2 P34913 1/20 0.39
▸ HPGDS O60760 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1068169 1.00 MEN1 (0.54) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL1068167 1.00 MEN1 (0.54) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL56416 0.91 HPGD (0.48) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL57238 0.91 HPGD (0.48) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL1335071 0.91 HPGD (0.48) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL16935663 0.88 HPGD (0.56) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL24683190 0.84 MEN1 (0.53) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL1333807 0.84 NR1H2 (0.50) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL20180767 0.83 MEN1 (0.52) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL56417 0.81 HPGD (0.54) ALDH1A1MAPTHPGDEPHX1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111699176-B Quinazolinones as PARP14 inhibitors 里邦医疗公司 2025-02-14 — — CN disclosed
US-11958837-B2 Quinazolinones as PARP14 inhibitors RIBON THERAPEUTICS, INC. (US) 2024-04-16 — — US disclosed
US-20230348475-A1 IMIDAZOPYRIDAZINE AND IMIDAZOPYRAZINE COMPOUNDS AS INHIBITORS OF CDK7 TRANSLATIONAL GENOMICS RES INST (US) 2023-11-02 — — US disclosed
US-20230348475-A1 IMIDAZOPYRIDAZINE AND IMIDAZOPYRAZINE COMPOUNDS AS INHIBITORS OF CDK7 TRANSLATIONAL GENOMICS RES INST (US) 2023-11-02 — — US disclosed
US-20230348475-A1 IMIDAZOPYRIDAZINE AND IMIDAZOPYRAZINE COMPOUNDS AS INHIBITORS OF CDK7 TRANSLATIONAL GENOMICS RES INST (US) 2023-11-02 — — US disclosed
EP-4212515-A1 QUINAZOLINONES AS PARP14 INHIBITORS Ribon Therapeutics Inc. (US) 2023-07-19 — — EP disclosed
EP-3728207-B1 QUINAZOLINONES AS PARP14 INHIBITORS RIBON THERAPEUTICS INC (US) 2023-02-01 — — EP disclosed
US-20230018702-A1 QUINAZOLINONES AS PARP14 INHIBITORS ABBVIE BIOTECHNOLOGY LTD (BM) 2023-01-19 — — US disclosed
US-20220388964-A1 (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS HIBERCELL, INC. 2022-12-08 — — US disclosed
WO-2022061155-A1 IMIDAZOPYRIDAZINE AND IMIDAZOPYRAZINE COMPOUNDS AS INHIBITORS OF CDK7 THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2022-03-24 — — WO disclosed
CN-111699176-A Quinazolinones as PARP14 inhibitors 里邦医疗公司 2020-09-22 — — CN disclosed
US-8624033-B2 Pleuromutilins and process for the preparation of pleuromutilins NABRIVA THERAPEUTICS AG (AT) 2014-01-07 — — US disclosed
US-20130053571-A1 PLEUROMUTILINS AND PROCESS FOR THE PREPARATION OF PLEUROMUTILINS NABRIVA THERAPEUTICS AG (AT) 2013-02-28 — — US disclosed
US-8334389-B2 Process for the preparation of pleuromutilins NABRIVA THERAPEUTICS AG (AT) 2012-12-18 — — US disclosed
EP-2069301-B1 PROCESS FOR THE PREPARATION OF PLEUROMUTILINS NABRIVA THERAPEUTICS AG (AT) 2011-09-07 — — EP disclosed
EP-2272829-A2 Process for the preparation of pleuromutilins Nabriva Therapeutics AG (AT) 2011-01-12 — — EP disclosed
US-20090253748-A1 PROCESS FOR THE PREPARATION OF PLEUROMUTILINS NABRIVA THERAPEUTICS AG (AT) 2009-10-08 — — US disclosed
EP-2069301-A1 PROCESS FOR THE PREPARATION OF PLEUROMUTILINS Nabriva Therapeutics Forschungs GmbH (AT) 2009-06-17 — — EP disclosed
WO-2008040043-A1 PROCESS FOR THE PREPARATION OF PLEUROMUTILINS NABRIVA THERAPEUTICS AG (AT) 2008-04-10 — — WO disclosed
EP-1908750-A1 Process for the preparation of pleuromutilins Nabriva Therapeutics Forschungs GmbH (AT) 2008-04-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11958837-B2 Quinazolinones as PARP14 inhibitors PARP14, PARP15, PARP11 MEN1 2734/4885ALDH1A1 2388/4885MAPT 2933/4885
US-20130053571-A1 PLEUROMUTILINS AND PROCESS FOR THE PREPARATION OF PLEUROMUTILINS PLEC, MLN, PTMA MEN1 1347/4885ALDH1A1 312/4885MAPT 2481/4885
US-20230348475-A1 IMIDAZOPYRIDAZINE AND IMIDAZOPYRAZINE COMPOUNDS AS INHIBITORS OF CDK7 CDK7, CDK8, CDKL4 MEN1 2666/4885ALDH1A1 3940/4885MAPT 1170/4885
US-20230018702-A1 QUINAZOLINONES AS PARP14 INHIBITORS PARP14, PARP15, PARP11 MEN1 2734/4885ALDH1A1 2388/4885MAPT 2933/4885
US-20090253748-A1 PROCESS FOR THE PREPARATION OF PLEUROMUTILINS PLEC, MLN, PTMA MEN1 1392/4885ALDH1A1 182/4885MAPT 2532/4885
US-20220388964-A1 (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS EIF2AK4, GCN1, GNAI2 MEN1 2812/4885ALDH1A1 1814/4885MAPT 4539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.